528-P: Different Glycemic Responses in People with T1 or T2DM after Use of an Insulin Injection Supporting App

Abstract

Lipohypertrophy, poor insulin injection technique and missed boluses are well-known issues in the management of diabetes but are sometimes overlooked. This study evaluated whether use of an app with digital training on correct injection routines, site rotation and injection related behaviors will improve glycemic control. Here, we present results of a post hoc analysis on CGM parameters. This was a prospective, open label study with patients on MDI (at least one basal and one bolus insulin injection), HbA1c ≥7% using an intermittent CGM device. A 4-week period without app use was followed by a 4-week period with the use of the app. Time below (<70mg/dl), in (70-180mg/dl), above (>180mg/dl) glycemic ranges, mean glucose, SD & CV were analyzed. 58 patients (37 male, 21 female) completed the study (mean age 52.0 ± 14.6y, diabetes duration 19.2 ± 12.5y, HbA1c 8.0 ± 0.8%, 35 T1DM, 23 T2DM). Overall (N=58), there were significant differences (p<0.001) between baseline and intervention for mean glucose (190.2 (39.2) vs 186.0 (42.0)), time in range (49.9 (17.1) vs 52.6 (18.3)) and time >180 mg/dl (48.2 (17.3) vs 45.4 (18.8)). No significant differences in % of values in hypoglycemia were observed. Table shows mean point estimates for differences from baseline for diabetes subgroups. The use of an insulin injection supporting app leads to improvements in glycemic measures with differences between people with T1DM & T2DM.. Disclosure J.Sieber: Employee; Becton, Dickinson and Company, embecta, Stock/Shareholder; Becton, Dickinson and Company, embecta. I.Wienbarg: None. E.Mahoney: None. T.Haak: None.